Worg Pharmaceuticals, a biopharmaceutical company dedicated to providing breakthrough immune therapy solutions, announced the successful closing of nearly RMB 400 million in its Series B financing. Investors in this round of funding included Junson Capital, Lapam Capital, Kaitai Capital, Puhua Capital, and Anji Ruixing Capital.

CEC Capital Group served as the financial advisor for Worg Pharmaceuticals in this transaction.

The funds raised in this round will primarily be utilized for the clinical development of their core products and team expansion. Additionally, it will accelerate the development of other products across various platforms to offer patients safer and more effective medications, meeting their clinical needs. This funding represents a pivotal milestone in Worg Pharmaceuticals' journey to establish itself as a globally recognized leader in the pharmaceutical industry.